Biologics that antagonize type 2 immune responses, such as IL-4 receptor subunit α (IL4R α) inhibitors, are effective in treating allergic diseases such as AD, asthma, EoE, and chronic rhinosinusitis with nasal polyps. Here, IL4R is linked to eosinophilic esophagitis.